Influence of MTHFR C677T and A1298C polymorphisms on the survival of pediatric patients with non-Hodgkin lymphoma. Issue 10 (24th August 2021)

• Record Type: Journal Article
• Authors: Zhu, Xiaoqin; Li, Wei; Zhu, Jia; Chen, Huimou; Guan, Jinqiu; Zhou, Dalei; Zhen, Zijun; Sun, Feifei; Huang, Junting; Wang, Juan; Sun, Xiaofei; Lu, Suying; Zhang, Yizhuo
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 10(2021)
• Page Start: 2374
• Page End: 2382
• Publication Date: 2021-08-24
• Subjects: MTHFR C677T polymorphism -- A1298C -- pediatric non-Hodgkin lymphoma -- survival; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2021.1927017
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: This study evaluated the influence of MTHFR C677T/A1298C polymorphisms on the survival of pediatric NHL. We enrolled 374 patients including 283 males and 91 females between 2014 and 2020. The median age was 9 years. The tumor types included Burkitt lymphoma ( n = 180), lymphoblastic lymphoma ( n = 95), anaplastic large cell lymphoma ( n = 64), and diffuse large B cell lymphoma ( n = 35). A subgroup of 158 patients were genotyped concerning C677T/A1298C polymorphisms. Neither C677T nor A1298C polymorphism was a significant factor in multivariate analysis. However, Kaplan-Meier analysis revealed that patients carrying 677 T allele had a significantly higher 5-year EFS rate in the whole group ( n = 158), and higher 5-year EFS/OS rates in the subgroup of BL/DLBCL than those with wild type. In conclusion, the C677T polymorphism could be used for survival prediction and potential risk stratification for further treatment protocols for Chinese pediatric NHL, especially for BL/DLBCL.